Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 18/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217661 | 0.91 | MTNR1A (0.41) | MTNR1AMTNR1BALOX15 | |
| SCHEMBL3221756 | 0.86 | HTR6 (0.35) | MTNR1AMTNR1BDRD2HTR2AALOX15 | |
| SCHEMBL3217329 | 0.86 | MTNR1A (0.35) | MTNR1AMTNR1BDRD2HTR2ADRD3 | |
| SCHEMBL3221335 | 0.86 | PDCD1 (0.35) | MTNR1AMTNR1BDRD2HTR2AALOX15 | |
| SCHEMBL3224173 | 0.84 | ALDH1A1 (0.35) | MTNR1AMTNR1BDRD2HTR2AALOX15 | |
| SCHEMBL3627280 | 0.83 | HTR6 (0.45) | HTR2A | |
| SCHEMBL3189384 | 0.80 | HTR6 (0.36) | MTNR1AMTNR1BALOX15 | |
| SCHEMBL3173604 | 0.80 | HTR6 (0.36) | MTNR1AMTNR1BALOX15 | |
| SCHEMBL3183373 | 0.80 | HTR6 (0.36) | MTNR1AMTNR1BALOX15 | |
| SCHEMBL3215142 | 0.79 | HTR6 (0.39) | MTNR1AMTNR1BDRD2HTR2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | claimed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | claimed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | MTNR1A 47/4885MTNR1B 39/4885DRD2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.